SCHEDULE: Baslake Partners Discloses 9.4% Stake in Neuphoria

Baslake Partners, along with its management entity and managing member, has disclosed a 9.4% beneficial ownership stake in Neuphoria Therapeutics Inc.

Summary

• Baslake Partners, LP, Baselake Management, LLC, and David Paolella (collectively, the 'Reporting Persons') have filed a Schedule 13G.
• The Reporting Persons beneficially own 222,222 shares of Neuphoria Therapeutics Inc.'s Common Stock.
• This ownership represents 9.4% of the outstanding Common Stock, based on 2,357,613 shares issued and outstanding as of September 29, 2025, as stated in the Issuer's 10-K.
• Baslake Partners, LP is the fund holding the shares, Baselake Management, LLC is the investment manager, and David Paolella is the managing member of the investment manager.
• All Reporting Persons share voting and dispositive power over the 222,222 shares.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of Neuphoria Therapeutics Inc.

Sentiment

Score: 6

Explanation: The filing is largely neutral, being a factual disclosure of ownership. The positive aspect comes from the transparency and the indication of a significant, passive institutional investment, which can be seen as a vote of confidence.

Positives

• Increased transparency regarding significant ownership in Neuphoria Therapeutics Inc.
• The filing indicates a passive investment intent, as the securities were not acquired for the purpose of changing or influencing control.

Negatives

• NA

Risks

• The filing itself does not present new risks for Neuphoria Therapeutics Inc., but rather discloses a significant ownership position.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Neuphoria Therapeutics Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• David Paolella, Managing Member of Baselake Management, LLC, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates a significant passive investment by an institutional entity in Neuphoria Therapeutics Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such disclosures are common for publicly traded companies and reflect investor interest.

Comparison to Industry Standards

• A 9.4% stake is a substantial position for an institutional investor, often indicating a strong conviction in the company's long-term prospects, similar to other biotech or pharma investments where specialized funds take significant positions.
• The passive investment intent, as certified, aligns with typical Schedule 13G filings by institutional investors who do not seek to actively influence management or corporate control, unlike activist investors who might file a Schedule 13D.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially signaling confidence in the company.
• Management: No direct impact on management or control, as the investment is declared passive.

Next Steps

• Neuphoria Therapeutics Inc. will continue its operations as usual.
• Baslake Partners, LP, Baselake Management, LLC, and David Paolella will continue to hold their investment in Neuphoria Therapeutics Inc. and will file updates if their ownership percentage changes significantly or if their investment intent shifts.

Key Dates

Keywords

Neuphoria Therapeutics, Baslake Partners, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals